SCHEMBL3149535

SCHEMBL3149535

NS(=O)(=O)c1ccc2c(ccc3ccccc32)c1

nearest known ligand 0.71

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.71
CA1 P00915 9/20 0.53
CA2 P00918 9/20 0.53
CA9 Q16790 8/20 0.53
CA12 O43570 5/20 0.53
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
ALDH1A1 P00352 2/20 0.50
HSD17B10 Q99714 2/20 0.50
HIF1A Q16665 1/20 0.50
CYP1B1 Q16678 1/20 0.50
PDPK1 O15530 1/20 0.49
GLO1 Q04760 1/20 0.49
MAPT P10636 1/20 0.49
HPRT1 P00492 1/20 0.48
TDP1 Q9NUW8 2/20 0.47
CYP2A6 P11509 1/20 0.46
TSHR P16473 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3140093 0.90 LMNA (0.68) LMNACA1CA2CA9CA12
SCHEMBL193716 0.84 LMNA (1.00) LMNACA1CA2CA9CA12
SCHEMBL8813715 0.82 ALDH1A1 (0.52) LMNAALDH1A1HSD17B10HIF1ACYP1B1
SCHEMBL3154840 0.82 LMNA (0.88) LMNACA1CA2CA9CA12
SCHEMBL28228467 0.82 LMNA (0.96) LMNACA1CA2CA9CA12
SCHEMBL8050037 0.81 ALDH1A1 (0.50) LMNAALDH1A1HSD17B10HIF1ACYP1B1
SCHEMBL11664505 0.81 HPRT1 (0.54) LMNAALDH1A1HSD17B10HIF1ACYP1B1
SCHEMBL392399 0.81 HSD17B10 (0.59) LMNAMEN1KMT2AALDH1A1HSD17B10
SCHEMBL2091021 0.79 HSD17B10 (0.58) MEN1KMT2AALDH1A1HSD17B10HIF1A
SCHEMBL30773501 0.79 HSD17B10 (0.58) MEN1KMT2AALDH1A1HSD17B10HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8394974-B2 Process for producing optically active chromene oxide compound NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2013-03-12 US disclosed
US-20100081808-A1 PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE EPOXY COMPOUND NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2010-04-01 US disclosed
EP-2133343-A1 PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE EPOXY COMPOUND Nissan Chemical Industries, Ltd. (JP) 2009-12-16 EP disclosed
EP-2003135-A9 PROCESS FOR PRODUCING OPTICALLY ACTIVE CHROMENE OXIDE COMPOUND Nissan Chemical Industries, Ltd. (JP) 2009-04-22 EP disclosed
US-20090043100-A1 Process for Producing Optically Active Chromene Oxide Compound NISSAN CHEMICAL INDUSTRIES, LTD (JP) 2009-02-12 US disclosed
EP-2003135-A2 PROCESS FOR PRODUCING OPTICALLY ACTIVE CHROMENE OXIDE COMPOUND Nissan Chemical Industries, Ltd. (JP) 2008-12-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100081808-A1 PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE EPOXY COMPOUND OSTC, EEF1D, SQLE LMNA 1929/4885CA1 1072/4885CA2 783/4885
US-20090043100-A1 Process for Producing Optically Active Chromene Oxide Compound CYP2C19, CYP2C9, CYP1A2 LMNA 2779/4885CA1 1412/4885CA2 338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.